Characterizing immune responses to zoonotic virus exposure in Cambodia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to characterize the immune response to zoonotic virus exposure in healthy adults aged 18 to 65 years in Cambodia. Participants will be individuals with high-risk exposure to animals or their excreta, such as those involved in guano farming or living near animal habitats. The study will involve the collection of whole blood samples to analyze immune signatures related to viruses like H5N1. The research is conducted by the International Center of Excellence in Research Cambodia with support from NIH investigators.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Capacity to provide informed consent.
2. Adult aged 18-65 years.
3. Have interaction with suspected infected animals within the last 2 years, including (but not limited to) the following risk factors:

   1. Hunting, slaughtering, or consuming suspected infected animals;
   2. Fruit collection, date palm sap harvesting, or tree pruning within agricultural plantations containing bat roosts;
   3. Bat guano farming;
   4. Ancillary work in live animal markets or wild animal habitats identified as likely containing infected animals (e.g., provision of cleaning, transportation, or tourism services);
   5. Living within 5 km of identified animal markets or wild animal habitats identified as likely containing infected animals.
4. Willing to allow biological samples and data to be stored for future research.

Exclusion Criteria:

1. Pregnancy (based on self-reporting).
2. Any underlying, chronic, or current medical condition that, in the opinion of the investigator, would interfere with participation in the study (e.g., inability or great difficulty in drawing blood, known anemia).
3. Self-reported symptoms suggestive of acute infection (acute myalgias, arthralgias, headache, retro-orbital pain, dyspnea, rash) within 7 days prior to enrollment.
4. Signs suggestive of acute infection (fever, defined as internal temperature \>38°C; hypoxemia, defined as peripheral oxygen saturation of \<90%; hypotension, defined as systolic blood pressure \<90 mm Hg or diastolic blood pressure \<50 mm Hg) present at screening.
5. Self-reported diagnosis of immune deficiency, including HIV infection, chronic corticosteroid use (≥10 mg prednisone dose or its equivalent for a continuous period of ≥30 days within the last 1 year), ongoing or prior (within the last 10 years) receipt of chemotherapy or immunotherapy, or current hematological malignancy.
6. Receipt of blood products, including immunoglobulin products, within 120 days of study enrollment.

Where it's running

• Communicable Disease Control Department
  Battambang, Cambodia Recruiting
• Communicable Disease Control Department
  Kampong Thom, Cambodia Recruiting
• Communicable Disease Control Department
  Kampot, Cambodia Recruiting
• Communicable Disease Control Department
  Stung Treng, Cambodia Recruiting
• Communicable Disease Control Department
  Takeo, Cambodia Recruiting

Study contacts

• Principal investigator: Christina Yek, MD — NIH/NIAID/Laboratory of Malaria and Vector Research (LMVR)
• Study coordinator: Chanthap Lon, MD
• Email: lonc@icercambodia.org
• Phone: 85512976799

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Expanding HIV-positive donor livers for HIV-positive recipients

  This study tests whether liver transplants from HIV-positive donors to HIV-positive recipients are safe regarding opportunistic infections and cancer.

  Recruiting at 2 sites National Institute of Allergy and Infectious Diseases (NIAID) · Baltimore, Maryland and 1 other locations · NCT07778459

• HIV vaccine test in healthy adults using CH505 nanoparticles and mRNA boosters

  This early-stage study will test the safety and immune responses of CH505 vaccine regimens in healthy adults to see if they can trigger HIV-specific immune protection.

  Recruiting at 2 sites Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · San Francisco, California and 7 other locations · NCT07757802

• Orally ingested yeast designed to express a tetra-specific anti-toxin for Clostridioides difficile safety study

  This first-in-human trial tests a yeast-based medicine (FZ002) to see if it is safe and tolerable for adults with no active infection, using a placebo for comparison.

  Recruiting Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · Knoxville, Tennessee · NCT07649096

• Using alpha-gal KO pork to see if it reduces reactions in people with Alpha-gal Syndrome

  This study tests whether eating pork that lacks the alpha-gal allergen lowers reaction risk for people with Alpha-gal Syndrome, using a crossover design where each participant tries both KO and wild-type pork on separate days.

  Recruiting Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · Little Rock, Arkansas and 3 other locations · NCT07611435

• DV700P-RNA and DV701B1.1-RNA HIV vaccines with ART interruption in adults with HIV

  This early-phase study tests two experimental HIV vaccines in adults living with HIV to see if they are safe and can help build antibody responses, with a closely monitored ART pause to observe immune effects.

  Recruiting at 4 sites Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · Birmingham, Alabama and 15 other locations · NCT07569029

• Reducing Immunosuppression by 50% in Young Liver Transplant Recipients

  This study tests whether cutting the immunosuppressive medicine by half in children with liver transplants is safe and effective.

  Recruiting at 7 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · San Francisco, California and 10 other locations · NCT07549503

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.